Acetylation and oxidation phenotypes in malignant lymphoma
- 1 January 1987
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 20 (3) , 235-238
- https://doi.org/10.1007/bf00570492
Abstract
101 white British adults with Hodgkin's disease or non-Hodgkin's lymphoma were phenotyped for acetylation status using dapsone and for oxidation status with debrisoquine prior to treatment. The frequencies of acetylation and oxidation phenotypes in these patients were compared with reference populations of normal subjects. No significant difference in phenotype frequency was found in the lymphoma patients. This suggests that neither of these metabolic polymorphisms for exogenous compounds is strongly associated with these malignancies. Owing to the small size of the study, however, an effect of these phenotypes could not be excluded.Keywords
This publication has 29 references indexed in Scilit:
- Genetically Determined Variability in Acetylation and Oxidation Therapeutic ImplicationsDrugs, 1985
- Genetically determined debrisoquine oxidation capacity in bladder cancerCarcinogenesis: Integrative Cancer Research, 1984
- The association of the slow acetylator phenotype with bladder cancer.Journal of Medical Genetics, 1983
- ROLE OF N-ACETYLTRANSFERASE PHENOTYPES IN BLADDER CARCINOGENESIS: A PHARMACOGENETIC EPIDEMIOLOGICAL APPROACH TO BLADDER CANCERThe Lancet, 1982
- Some observations on the oxidation phenotype status of Nigerian patients presenting with cancerCancer Letters, 1981
- Comparison of normal and asthmatic circadian rhythms in peak expiratory flow rate.Thorax, 1980
- Cancer and other causes of death among U.S. veterinarians, 1966–1977International Journal of Cancer, 1980
- MALIGNANT LYMPHOMA OF HISTIOCYTIC TYPE AND EXPOSURE TO PHENOXYACETIC ACIDS OR CHLOROPHENOLSThe Lancet, 1979
- Acetylator Phenotype in Patients with Breast CancerOncology, 1978
- LYMPHOMAS AND ANIMAL-PROTEIN CONSUMPTIONThe Lancet, 1976